Abstract
Poloxamer (Pluronic®) nonionic surfactant vehicles are a series of chemically-related block copolymers finding widespread use in parenteral formulations as solubilizing and wetting agents for traditional, low-molecular weight organic drug molecules, as well as stabilizing agents for proteins and polypeptide drugs. We report the effects of poloxamer 407 (Pluronic® F-127) on plasma cholesterol and triglyceride concentrations in rats. Poloxamer 407 injected into rats by intraperitoneal injection (dose = 1.5 gm/kg) resulted in sustained (greater than 96 hour) hypercholesterolemia and hypertriglyceridemia. A larger dose of poloxamer 407 was required to elevate plasma triglyceride relative to total cholesterol. Ingestion of commercial rat chow had a negligible effect on plasma cholesterol and triglycerides levels in control (no poloxamer injection) animals, but consumption of food by animals that received an intraperitoneal injection of poloxamer 407 (30% w/w) resulted in significantly (p <.05) greater elevations in plasma cholesterol and triglycerides than in fasted animak administered poloxamer 407. The route of poloxamer 407 administration, namely intramuscular vs. intraperitoneal injection, was observed to be a more important factor for poloxamer-induced elevations in plasma cholesterol than poloxamer-mediated elevations in plasma triglycerides. Our results also provide suggestive evidence that the mechanism responsible for the elevation of plasma cholesterol following intraperitoneal injection of a poloxamer 407 solution (30% w/w) to rats may be due to stimulation of 3-hydroxy-3-methylglutaryl-co-enzyme A (HMG-CoA) reductase activity in the liver by the poloxamer vehicle. Oral administration of lovastatin (dose = 75mg/kg/day × 3 day) to rats prior to intraperitoneal injection of a solution of poloxamer 407 (30% w/w) completely inhibited elevations in plasma cholesterol and triglycerides. Thus, this preliminary investigation has identified a vehicle which, when injected intraperitoneally to rats, produces sustained hypercholesterolemia and hypertriglyceridemia. Elevated levels of plasma cholesterol and triglycerides resulting from the chronic administration of poloxamer-containing (? 1-2% w/w) drug formulations to patients may potentially hinder therapeutic outcome. The animal model presented here for the chemical induction of hypercholesterolemia and hypertriglyceridemia in rats may represent an inexpensive, reliable, and rapid means with which to screen new chemical entities designed to inhibit HMG-CoA reductase activity and lower both total plasma cholesterol and triglycerides.
- Received December 27, 1991.
- Accepted May 25, 1992.
- Copyright © Parenteral Drug Association. All rights reserved.
PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.
If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing.
Full issue PDFs are for PDA members only.
Note to pda.org users
The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.